Basel, Switzerland – Lonza announced today it has completed the acquisition of Capsugel S.A. from KKR for $5.5 billion in cash, including refinancing of Capsugel’s approximate $2 billion in debt.
Capsugel is a leader in advanced oral dosage delivery technologies and hard capsules. The acquisition goes along with Lonza’s stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing offerings and opening up new market opportunities in pharma, consumer healthcare and nutrition.
With the acquisition of Capsugel and its breadth of technologies, Lonza believes it will expand the market reach of both companies’ contract development and manufacturing organization (CDMO) and products businesses. It also supports Lonza’s strategic ambition to get closer to the patient and end consumer.
“Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration,” said Lonza CEO Richard Ridinger, in a statement.
Capsugel’s business will continue to operate in its existing structure until the full integration has been completed, the company said.
Published on WholeFoods Online July 6, 2017